Ocaliva Exit Could Help Ipsen And Gilead’s New Cholangitis Entrants

 
• By Andrew McConaghie

The FXR agonist drug is facing market removal in the EU and possibly the US, which could open the door for two new PPAR agonist therapies.

Gilead
Gilead and Ipsen/Genfit's products could benefit from an EU withdrawal of the drug. • Source: Shutterstock

More from New Products

More from Scrip